Abstract
Our laboratory has been developing new inhibitors of a key regulatory enzyme of testicular and adrenal androgen synthesis 17α-hydroxylase/C17,20-lyase (P450c17), with the aim of improving prostate cancer treatment. We designed and evaluated two groups of azolyl steroids: Δ5-non-competitive inhibitors (Δ5NCIs), VN/63-1, VN/85-1, VN/87-1 and their corresponding Δ4 derivatives (Δ4NCIs), VN/107-1, VN/108-1 and VN/109-1. The human P450c17 gene was transfected into LNCaP human prostate cancer cells, and the resultant LNCaP-CYP17 cells were utilized to evaluate the inhibitory potency of the new azolyl steroids. VN/85-1 and VN/108-1 had the lowest IC50 values of 1.25 ± 0.44 nM and 2.96 ± 0.78 nM respectively, which are much lower than that of the known P450 inhibitor ketoconazole (80.7 ± 1.8 nM). To determine whether the compounds had direct actions on proliferation of wild-type LNCaP cells, cell growth studies were performed. All of the Δ5NCIs and VN/108-1 blocked the growth-stimulating effects of androgens. In steroid-free media, the Δ5NCIs decreased the proliferation of LNCaP cells by 35–40%, while all of the Δ4NCIs stimulated LNCaP cells growth 1.5- to 2-fold. In androgen receptor (AR) binding studies, carried out to determine the mechanism of this effect, all of the Δ4NCIs (5 μM) displaced 77–82% of synthetic androgen R1881 (5 nM) from the LNCaP AR. The anti-androgen flutamide and the Δ5NCIs displaced 53% and 32–51% of R1881 bound to AR respectively. These results suggested that the Δ5NCIs may also be acting as anti-androgens. We further evaluated our inhibitors in male severe combined immuno- deficient mice bearing LNCaP tumour xenografts. In this model VN/85-1 was as effective as finasteride at inhibiting tumor growth (26% and 28% inhibition, respectively) and the inhibitory effect of VN/87-1 was similar to that of castration (33% and 36% inhibition respectively). These results suggest that VN/85-1 and VN/87-1 may be potential candidates for treatment of prostate cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Berns, EMJJ, de Boer, W & Mulder, E (1993) Androgen-dependent growth regulation of and release of specific proteins by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate 23: 213–223
Chung, B, Picado-Leonard, J, Hahju, M, Bienkowski, M, Hall, PF, Shively, JE & Miller, WL (1987). Proc Natl Acad Sci USA 84: 407–411
Crawford, ED, Eisenberg, M, McLeod, DG, Spaulding, JT, Benson, R, Dorr, FA, Blumstein, BA, Davis, MA & Goodman, PJ (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321: 419–424
Crawford, ED, Eisenberg, M & McLeod, DG (1992) Treatment of newly diagnosed stage D2 prostate cancer with leuprolide and flutamide or leuprolide alone, phase III, prognostic significance of minimal disease. J Urol 147: 417A
De Launoit, Y, Veilleux, R, Dufour, M, Simard, J & Labrie, F (1991) Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res 51: 5165–5170
Denis, L (1994) Role of maximal androgen blockage in advanced prostate cancer. Prostate 5 (suppl): 17–22
Gormley, GJ (1991) Role of 5α-reductase inhibitors in the treatment of advanced prostatic carcinoma. Urol Clin North Am 18: 93–97
Gormley, GJ, Stoner, E, Bruskewitz, RC, Imperato-McGinley, J, Walsh, PC, McConnell, JD, Andriole, GL, Geller, J, Bracken, BR, Tenover, JS, Vaughan, ED, Pappas, ED, Taylor, A, Binkowitz, B & Ng, J (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992 327: 1185–1191
Grigoryev, DN, Kato, K, Njar, VCO, Long, BJ, Ling, Y-z, Wang, X, Mohler, J & Brodie, AMH (1999) Cytochrome P450c17 expressing E.coli as a first-step screening system for 17α-hydroxylase-C17,20-lyase inhibitors. Analyt Biochem 267: 319–330
Horoszewicz, JS, Lying, SS, Kawinski, E, Karr, JP, Rosental, H, Chu, TM, Mirand, EA & Murphy, GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43: 1809–1818
Jubilerer, SJ & Hogan, T (1989) High dose ketoconazole for the treatment of hormone-refractory metastatic prostate cancer: 16 cases and review of the literature. J Urol 142: 89–91
Klus, GT, Nakamura, J, Li, J-s, Ling, Y-z, Son, C, Kemppainen, JA, Wilson, EM & Brodie, AMH (1996) Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Cancer Res 56: 4956–4964
Ling, Y, Li, J, Liu, Y, Kato, K, Klus, GT & Brodie, AMH (1997) 17-Imidazolyl, pyrazolyl, and isoxazolyl androstene derivatives. Novel steroidal inhibitors of human cytochrome C17,20-lyase (P45017α). J Med Chem 40: 3297–3304
Nakajin, S, Hall, PF & Onoda, M (1981) Testicular microsomal P-450 for C21 steroid side chain cleavage: spectral and binding studies. J Biol Chem 256: 6134–6139
Njar, VCO, Kato, K, Nnane, IP, Grigoryev, DN, Long, BJ & Brodie, AMH (1998) Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17α-hydroxylase-C17,20-lyase (P45017α): potential agents for the treatment of prostate cancer. J Med Chem 41: 902–912
Pousette, A, Carlstrom, K, Henriksson, P, Grande, M & Stege, R (1997) Use of a hormone-sensitive (LNCaP) and a hormone-resistant (LNCaP-r) cell line in prostate cancer research. Prostate 31: 198–203
Sartor, O, Cooper, M, Weinberger, M, Headlee, D, Thibault, A, Tomkins, A, Steinberg, S, Figg, WD, Linehan, WM & Myers, CE (1994) Surprising activity of flutamide withdrawal, when combined with aminoglutethimide in treatment of ‘hormone-refractory’ prostate cancer. J Natl Cancer Inst 86: 222–227
Sato, N, Gleave, ME, Bruchovsky, N, Rennie, PS, Beraldi, E & Sullivan, LD (1997) A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 57: 1584–1589
Schuurmans, AL, Bolt, J, Veldscholte, J & Mulder, E (1991) Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J Steroid Biochem Mol Biol 40: 193–197
Shibata, A, Ma, J & Whittemore, AS (1998) Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 90: 1230–1231
Small, EJ, Baron, A & Bok, R (1997) Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer 80: 1755–1759
Trachtenberg, J & Pont, A (1984) Ketoconazole therapy for advanced prostatic cancer. Lancet 2: 433–435
Veldscholte, J, Ris-Stalpers, C, Kuiper, GGJM, Jenster, G, Berrevoets, C, Claassen, E, Van Rooij, HCJ, Trapman, J, Brinkmann, AO & Mulder, E (1990) A mutation in the ligand-binding domain of the androgen receptor of human LNCaP cells affects steroidal binding characteristics and response to androgens. Biochem Biophys Res Comman 173: 534–540
Veldscholte, J, Berrevoets, C, Brinkmann, AO, Grootegoed, JA & Mulder, E (1992) Androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction and transcription activation. Biochem 31: 2393–2399
Visakorpy, T, Hyytinen, E, Koivisto, P, Tanner, M, Keinanen, R, Palmberg, C, Palotie, A, Tammela, T, Isola, J & Kallioniemi, O-P (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9: 401–406
Webber, MM, Bello, D & Quader, S (1997) Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications Part 2. Tumorigenic cell lines. Prostate 30: 58–64
Wilding, G, Chen, M & Gellman, EP (1989) Aberrant response in vitro of hormone responsive prostate cancer cells to antiandrogens. Prostate 14: 103–115
Williams, G, Kerle, DJ, Doble, A, Dunlop, H, Smith, C, Allen, J, Yeo, T & Bloom, SR (1986) Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br J Urol 58: 45–51
Wong, C, Kelce, WR, Sar, M & Wilson, EM (1995) Androgen receptor antagonist versus agonist activities of the fungicide vinclozin relative to hydroxyflutamide. J Biol Chem 270: 19998–20003
Author information
Authors and Affiliations
Additional information
Correspondence to:AMH Brodie
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Grigoryev, D., Long, B., Nnane, I. et al. Effects of new 17α-hydroxylase/C17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo. Br J Cancer 81, 622–630 (1999). https://doi.org/10.1038/sj.bjc.6690739
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.bjc.6690739
Keywords
This article is cited by
-
Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice
British Journal of Cancer (2006)
-
Pharmacokinetics of novel inhibitors of androgen synthesis after intravenous administration in mice
Cancer Chemotherapy and Pharmacology (2003)
